Brief: Shenzhen Hepalink Pharmaceutical Says Exarane Approved By New Zealand Medicines And Medical Devices Safety Authority
28/03/2024 15:13
March 28 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group Co Ltd 002399.SZ :
* EXARANE APPROVED BY NEW ZEALAND MEDICINES AND MEDICAL
DEVICES
SAFETY AUTHORITY FOR SALES IN MARKET
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA